Skip to main content
. 2018 Feb 14;12(2):e0006264. doi: 10.1371/journal.pntd.0006264

Table 3. Details and summary of the diagnostic performance of different studies using LAMP for VL diagnosis compared to our study.

Studies
Ghasemian et al.
[28]a
Verma et al.
[29]b
Verma et al.
[30]c
Khan et al.
[31]d
This studye
Country Iran India India Bangladesh Sudan
LAMP target kDNA kDNA kDNA kDNA kDNA and 18SrRNA
Primer specificity L. infantum L. donovani L. donovani, L. major, L. tropica L. donovani Leishmania genus
Study population 47 VL cases
40 controls
55 VL cases
68 controls
66 VL cases
100 controls
75 VL cases
101 controls
185 VL suspects
Clinical specimen tested Buffy coat Whole blood
BMA
Whole blood
BMA
Buffy coat Whole blood
Buffy coat
DNA purification method QIAamp Mini Kit (QIAgen) QIAamp Mini Kit (QIAgen) QIAamp Mini Kit (QIAgen) QIAamp Mini Kit (QIAgen) QIAamp Mini Kit (QIAgen) and
Boil & Spin
Reference test DAT (>1:3200) and BMA microscopy BMA microscopy and qPCR on blood and BMA rK39 RDT-positive patients confirmed by qPCR Spleen aspirate microscopy Lymph node aspirate microscopy
Sensitivity BC 93.60% WB 96.4%
BMA 100%
WB 96.6%
BMA 100%
BC 90.70% WB-B&S 97.6%
WB-QIA 100%
BC-B&S 95.2%
BC-QIA 97.6%
Specificity 100% 98.5% 100% 90.7% 99.01

a Controls in [28]: 30 healthy controls from non-endemic area and 10 non-VL patients (malaria, TB, toxoplasmosis, hepatitis herpes virus). b Controls in [29]: 34 HC-E, 5 malaria, 5 TB, 18 leprosy, 6 fungal diseases. c Controls in [30]: 24 HC-E, 38 HC-NE, 7 malaria, 7 TB, 18 leprosy, 6 fungal diseases. d Controls in [31]: 25 HC-E, 26 HC-NE, 25 TB, 25 other diseases. e Data from the 185 VL suspects tested by all methods.

BC: buffy coat. BMA: bone marrow aspirate. B&S: boil & spin. DAT: direct agglutination test. HC-E: healthy controls from endemic region. HC-NE: healthy controls from non-endemic region. kDNA: kDNA minicircles. QIA: QIAamp DNA Mini Kit. VL: visceral leishmaniasis. WB: whole blood.